4.7 Review

Exosomes: new molecular targets of diseases

Journal

ACTA PHARMACOLOGICA SINICA
Volume 39, Issue 4, Pages 501-513

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/aps.2017.162

Keywords

exosomes; microvesicles; noncoding RNAs; biomarker; drug delivery; exosome mimics

Funding

  1. American Heart Association [16GRNT30950010]
  2. National Institutes of Health COBRE grant [P20GM104936]
  3. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104936] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Extracellular vesicles (EVs) comprise apoptotic bodies, microvesicles and exosomes, and they perform as key regulators in cell-to-cell communication in normal as well as diseased states. EVs contain natural cargo molecules, such as miRNA, mRNA and proteins, and transfer these functional cargos to neighboring cells or more distant cells through circulation. These functionally active molecules then affect distinct signaling cascades. The message conveyed to the recipient cells is dependent upon the composition of the EV, which is determined by the parent cell and the EV biogenesis. Because of their properties such as increased stability in circulation, biocompatibility, low immunogenicity and toxicity, EVs have drawn attention as attractive delivery systems for therapeutics. This review focuses on the functional use of exosomes in therapy and the potential advantages and challenges in using exosomes for therapeutic purposes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available